Date Added: 20/03/2017
Date Updated: 20/03/2017
Avelumab for advanced non-small cell lung cancer — first line
Specialties: Oncology & radiotherapy
Technology Type: Drugs
Stage of development: Investigational - phase III
Stage of EAA: Prioritised for assessment
Non-small cell lung cancer (NSCLC).
Programmed death ligand 1 (PD-L1) positive.
Stage of disease
Advanced, metastatic or recurrent disease.
Place in Treatment